Jenscare completes first implants in FDA pivotal trial for LuX-Valve Plus tricuspid valve system

• Jenscare completed first-batch implantations in an FDA IDE pivotal trial for its LuX-Valve Plus transvenous tricuspid valve replacement system.
• Trial uses a global, multicenter, randomized head-to-head design versus Edwards Lifesciences’ EVOQUE system to assess safety and efficacy in severe tricuspid regurgitation.
• Milestone follows EU MDR CE certification, supporting the group’s push to expand internationally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12246301), on July 16, 2026, and is solely responsible for the information contained therein.